Apac Point Care Testing Poct Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2022 –2029 |
 시장 규모(기준 연도) |
USD 29.00 Billion |
 시장 규모(예측 연도) |
USD 64.46 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
>아시아 태평양 진료소 검사(POCT) 시장 , 제품별(포도당 모니터링 제품, 심장대사 검사 제품, 감염성 질환 검사 제품, 임신 및 생식 능력 검사 제품, 종양/암 마커 검사 제품, 요분석 검사 제품, 콜레스테롤 검사 제품, 혈액학 검사 제품, 약물 남용 검사 제품, 분변 잠복 검사 제품, 신속 응고 검사 및 기타 POC 제품), 응용 분야(혈액 수혈, 심장 모니터링, 응고, 혈당, 혈액학, 비침습적 SPO2 모니터링, 비침습적 PCO2 모니터링, 전혈 분석, 생체 신호 모니터링 및 기타), 플랫폼(측면 흐름 검사/면역 크로마토그래피 검사, 딥스틱, 미세 유체 역학, 분자 진단 및 면역 검사), 처방 모드(처방 기반 검사 및 OTC 검사), 검사 유형(면역 검사, 세포 기반 검정, 핵산 증폭 검사, 임상 화학 검정 및 혈액학), 최종 사용자(병원, 진료소, 실험실, 홈 케어, 외래 수술 센터 및 기타), 유통 채널(직접 입찰 및 소매 약국) - 2029년까지의 산업 동향 및 예측
시장 분석 및 규모
환자와 가까운 곳에서 수행할 수 있는 검사로 정의되는 진료 시점 검사는 결과와 모니터링을 기반으로 바로 의학적 선택을 할 수 있습니다 . 진료 시점 검사(POCT)는 환자 검사라고도 하며, 의사는 몇 시간이 아닌 몇 분 만에 정확한 실시간 실험실 수준의 진단 결과를 평가할 수 있습니다. 환자가 필요할 때, 필요한 곳에서 가능한 가장 효과적이고 효율적인 치료를 받을 수 있도록 보장합니다.
Data Bridge Market Research는 2021년에 290억 달러였던 진료 시점 검사(POCT) 시장이 2029년까지 644억 6천만 달러로 급증할 것으로 분석했으며, 2022년부터 2029년까지 예측 기간 동안 10.5%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.
시장 정의
POC 검사는 양이 적고 비용이 많이 들기 때문에 중앙 실험실 검사만큼 선호되지 않습니다. 이는 POC 검사에 대해 별도의 코드를 제공해야 하는 청구 시스템에 추가적인 부담을 줍니다. 이로 인해 경험이 없거나 새로 고용된 직원의 청구 오류가 발생할 수 있으며, 검사 코드가 일치하지 않아 데이터 관리 시스템에 데이터를 입력하지 못할 수도 있습니다.
보고 범위 및 시장 세분화
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2014-2019로 사용자 정의 가능) |
|
양적 단위 |
매출은 10억 달러, 볼륨은 단위, 가격은 10억 달러 |
|
다루는 세그먼트 |
Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) |
|
Market Players Covered |
Abbott (U.S), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S), Danaher (U.S), Sekisui Diagnostics (U.S), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S), Beckman Coulter, Inc. (U.S), PTS Diagnostics (U.S), Nova Biomedical (U.S), Chembio Diagnostics, Inc. (U.S), Quidel Corporation (U.S) and Sienco, Inc (U.S) |
|
Market Opportunities |
|
Point-of-Care Testing (POCT) Market Dynamics
Drivers
- Upward trend in disease prevalence in the developing countries
Chronic diseases and acute infections are on the rise in developing countries, owing to a lack of health awareness, poor medical infrastructure, and a sedentary lifestyle, among other causes. As a result of these circumstances, diagnosis and treatment are delayed, as is the quality of care obtained. The need for point-of-care tests for rapid diagnosis is growing due to their convenience of use, cost-effectiveness, and small product size.
- Benefits related with OTC-based test
The point of care testing market for TC tests is expected to develop at a 7.1% CAGR through 2027, owing to an increase in OTC testing such as pregnancy tests and blood glucose tests that deliver results in a matter of seconds. These examinations do not necessitate the use of a skilled specialist and may be performed by individuals themselves, propelling the industry forward. The First Response kit, for example, is a quick pregnancy test that provides a response in 60 seconds. Accu-Chek active blood glucose metre kits also give customers with readings in 5 seconds, boosting market demand.
- Increasing incidence rate of diabetes and obesity lead to cardiovascular illness
The increased prevalence of diabetes and obesity, the point of care testing market for cardio metabolic testing is predicted to exceed USD 5.3 billion by 2027. The cardiometabolic test also determines the percentage level of Docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) in red blood cell membrane.This also aids in the identification of new risk factors for cardiac arrest and other heart-related disorders.
Opportunities
- Technological advancement in lateral flow assay
The market for lateral flow assays in point of care testing is expected to reach USD 11.8 billion by 2027. The industry's growth will be aided by the launch of novel products that will allow for rapid advancement in the research and development (R&D) of point-of-care testing (POCT) diagnostic tools. In addition, advances in component materials, reader technologies, reagents, and sensitivity increase have made quantitative results more possible with the use of lateral flow assay, supporting sector growth.
Restraints/Challenges
- Stringent regulatory policies
Due to tight and time-consuming regulatory requirements, the point of care testing industry is growing slowly. With the expanding area of use and increased adoption in developing economies, regulators are placing a greater emphasis on point-of-care testing (POCT) compliance, safety, and usability. Point-of-care testing are classed as class II medical devices by the US Food and Drug Administration. These devices provide a reasonable guarantee of the device's effectiveness and safety.
- Lack of alignment with definitive central lab methods
Unsuitable indications for the performance of the test, inappropriate sampling times and techniques, a lack of information about the patient's condition, and other factors such as fasting before functional tests or variations in posture/position during similar tests are all examples of pre-analytical errors for POC testing.
This point-of-care testing (POCT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point-of-care testing (POCT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Point-of-Care Testing (POCT) Market
The growing use of point-of-care tests that can quickly identify COVID-19, the point-of-care diagnostics market will rise significantly in 2022. Point-of-care testing has become an important diagnostic technique due to the necessity for quick diagnostic results. Rapid antigen testing kits that can be utilised efficiently in point-of-care settings are in high demand due to the rapidly increasing number of COVID-19 cases and the growing pressure on governments to enhance patient management. Different significant reasons projected to fuel the long-term growth of the point-of-care diagnostics market are the rising prevalence of other respiratory disorders around the world, the shift toward decentralised diagnostics, and enhanced access to point-of-care devices through online platforms.
Recent Development
Roche introduced its Cobas Pulse System in select countries accepting the CE Mark in January 2022. This is the latest generation of linked point-of-care solutions for professional blood glucose management from Roche Diagnostics.
In October 2021, Thermo Fisher Scientific announced that it had received FDA Emergency Use Authorization (EUA) to run COVID-19 tests with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device, a high-throughput, automated COVID-19 testing system on the Amplitude Solution, using a new saliva sample collection method.
The SPECIFIC REVEAL Rapid AST system was co-exclusively distributed in Europe by bioMérieux and Specific Diagnostics in June 2021. The system works in tandem with bioMérieux's BIOFIRE BCID2.
Asia-Pacific Point-of-Care Testing (POCT) Market Scope
The point-of-care testing (POCT) market is segmented on the basis of product, technology, prescription, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Glucose Monitoring
- Strips
- Meters
- Lancets
- Cardiometabolic testing
- Cardiac marker testing
- hsTnl
- BNP
- D-dimer
- CK-MB
- Myoglobin
- Others
- Blood gas/electrolytes testing
- HBA1C testing
- 감염병 검사
- 인플루엔자 검사
- HIV 검사
- C형 간염 검사
- 성병(STD) 검사
- 의료 관련 감염(HAI) 테스트
- 호흡기 감염 검사
- 열대병 검사
- 기타 감염병 검사
- 응고 테스트
- PT/INR 테스트
- 활성화 응고 시간(ACT/APTT) 테스트
- 임신 및 생식력 검사
- 임신 테스트
- 생식력 검사
- 종양/암 마커 검사
- 요분석 검사
- 콜레스테롤 검사
- 혈액학 검사
- 약물 남용 테스트
- 대변 잠복 검사
- 기타
기술
- 측면 흐름 분석
- 딥스틱
- 마이크로유체학
- 분자진단
- 면역 검정법
- 응집 분석
- 통과하다
- 고체상
- 바이오센서
처방
- OTC 테스트
- 처방 기반 테스트
애플리케이션
- 심장대사검사
- 감염병 검사
- 신장학 검사
- 약물 남용(DoA) 테스트
- 혈당 검사
- 임신 테스트
- 암 바이오마커 검사
- 다른 응용 프로그램
최종 사용자
- 병원
- 진단 센터
- 연구실
- 홈 케어 설정
- 기타
유통 채널
- 직접 입찰
- 소매 약국
진료 시점 검사(POCT) 시장 지역 분석/통찰력
진료시점 검사(POCT) 시장을 분석하고, 위에 언급된 대로 국가, 제품, 기술, 처방, 애플리케이션 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
진료시점 검사(POCT) 시장 보고서에서 다루는 국가는 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 아시아 태평양(APAC)의 기타 국가입니다.
중국은 병원 운영, 응급실, 중환자 치료, 만성질환 예방 및 관리, 공중보건 비상사태, 지방 의료기관 건설, 새로운 농촌 지원 의료 등 분야에서 중국의 진료시점 검사(POCT) 제품이 엄청난 적용 범위를 갖고 있기 때문에 시장을 장악할 것으로 예상됩니다.
일본은 HIV 및 기타 질병으로 고통받는 사람들의 수가 증가함에 따라 시장을 지배할 것이며, 이는 국가에서 진료 시점 검사 장치에 대한 높은 승인율로 이어질 것입니다. 인도는 국민들 사이에서 질병이 많이 유행하기 때문에 지배적인 국가입니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
의료 인프라 성장 설치 기반 및 신기술 침투
진료 시점 검사(POCT) 시장은 또한 모든 국가에 대한 자세한 시장 분석을 제공합니다. 자본 장비에 대한 의료 지출 증가, 진료 시점 검사(POCT) 시장을 위한 다양한 종류의 제품 설치 기반, 수명선 곡선을 사용하는 기술의 영향, 의료 규제 시나리오의 변화 및 진료 시점 검사(POCT) 시장에 미치는 영향. 데이터는 2010-2020년의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 진료 시점 테스트(POCT) 시장 점유율 분석
진료 시점 검사(POCT) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 진료 시점 검사(POCT) 시장과 관련된 회사의 초점에만 관련이 있습니다.
POCT(Point-of-Care Testing) 시장에서 활동하는 주요 기업은 다음과 같습니다.
- 애벗(미국)
- F. 호프만-라 로슈 유한회사(스위스)
- BD(미국)
- 지멘스 헬스케어 프라이빗 리미티드(독일)
- Bio-Rad Laboratories, Inc. (미국)
- 다나허(미국)
- 세키스이 다이어그노스틱스(미국)
- 트리니티 바이오텍(아일랜드)
- bioMérieux (프랑스)
- EKF 진단(독일)
- AccuBioTech Co., Ltd. (중국)
- 계측 실험실(미국)
- Beckman Coulter, Inc. (미국)
- PTS 진단(미국)
- 노바 바이오메디컬(미국)
- Chembio Diagnostics, Inc. (미국)
- 퀴델 코퍼레이션(미국)
- 시엔코 주식회사(미국)
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 LIST OF DISTRIBUTORS IN ASIA PACIFIC REGION FOR POINT-OF-CARE-TESTING MARKET
5 COVID-19 IMPACT ON ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
5.1 IMPACT ON DEMAND
5.2 PRICE IMPACT
5.3 IMPACT ON SUPPLY CHAIN
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS
5.5 CONCLUSION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 GROWING POPULARITY OF WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES
6.1.4 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING
6.3.3 TECHNOLOGICAL ADVANCEMENTS IN POINT-OF-CARE TESTING DEVICES
6.4 CHALLENGE
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.1.1 GLUCOSE MONITORING PRODUCTS
7.1.1.1 STRIPS
7.1.1.2 METERS
7.1.1.3 LANCETS & LANCING DEVICES
7.1.2 INFECTIOUS DISEASE TESTING PRODUCTS
7.1.2.1 INFLUENZA
7.1.2.2 HIV TESTING PRODUCTS
7.1.2.3 HEPATITIS C
7.1.2.4 SEXUALLY TRANSMITTED DISEASE (STD)
7.1.2.5 HEALTHCARE-ASSOCIATED INFECTION (HAI)
7.1.2.6 RESPIRATORY INFECTION
7.1.2.7 TROPICAL DISEASE
7.1.2.8 OTHER INFECTIOUS DISEASE
7.1.3 CARDIOMETABOLIC TESTING PRODUCTS
7.1.3.1 BLOOD GAS/ELECTROLYTES
7.1.3.2 HBA1C TESTING PRODUCTS
7.1.3.3 CARDIAC MARKER TESTING PRODUCTS
7.1.3.4 LIPID TESTING KITS
7.1.4 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.1.4.1 PREGNANCY TESTING PRODUCTS
7.1.4.2 FERTILITY TESTING PRODUCTS
7.1.5 HEMATOLOGY TESTING PRODUCTS
7.1.5.1 BLOOD ANAYZER
7.1.5.2 REAGENTS AND KITS
7.1.6 RAPID COAGULATION TESTING
7.1.6.1 COAGULATION ANALYZER
7.1.6.2 TESTING KIT
7.2 DRUGS-OF-ABUSE TESTING PRODUCTS
7.3 URINALYSIS TESTING PRODUCTS
7.4 CHOLESTEROL TESTING PRODUCTS
7.5 TUMOR/CANCER MARKER TESTING PRODUCTS
7.6 FECAL OCCULT TESTING PRODUCTS
7.7 OTHER POC PRODUCTS
8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 BLOOD GLUCOSE
8.3 CARDIAC MONITORING LUCOSE
8.4 HAEMATOLOGY
8.4.1 WBC COUNT
8.4.2 DNA SEQUENCING REAGENTS & KITS
8.5 COAGULATION
8.6 WHOLE BLOOD ANALYSIS
8.6.1 BLOOD GASES
8.6.2 ELECTROLYTES & METABOLITES
8.7 VITAL SIGN MONITORING
8.7.1 HEART RATE
8.7.2 BLOOD PRESSURE
8.7.3 RESPIRATORY RATE 59.37
8.7.4 TEMPERATURE
8.8 NON- INVASIVE SPO2 MONITORING
8.9 NON- INVASIVE PCO2 MONITORING
8.1 BLOOD TRANSFUSION
9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM
9.1 OVERVIEW
9.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS
9.3 DIPSTICKS
9.4 MOLECULAR DIAGNOSTICS ENOME SEQUENCING
9.5 IMMUNOASSAYS
9.6 MICROFLUIDICS
10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE
10.1 OVERVIEW
10.2 OTC TESTING
10.3 PRESCRIPTION-BASED TESTING
11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE
11.1 OVERVIEW
11.2 IMMUNOASSAYS
11.3 NUCLEIC ACID AMPLIFICATION TESTING
11.4 HAEMATOLOGY
11.5 CLINICAL CHEMISTRY ASSAYS
11.6 CELL-BASED ASSAYS
12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER
12.1 OVERVIEW
12.2 CLINICS
12.3 HOME CARE
12.4 HOSPITALS
12.5 LABORATORIES
12.6 AMBULATORY SURGICAN CENTERS
12.7 OTHERS
13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL PHARMACIES
14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET BY COUNTRY
14.1 OVERVIEW
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 THAILAND
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F.HOFFMANN-LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHCARE PRIVATE LIMITED
17.2.1 COMPANY SNAPSHOT
17.2.1 PRODUCT PORTFOLIO
17.2.2 RECENT DEVELOPMENTS
17.3 BD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.4 DANAHER
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENTS
17.5 BIOMÉRIEUX SA
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ACCUBIOTECH CO.,LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 BECKMAN COULTER,INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BIO-RAD LABORATORIES, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CHEMBIO DIAGNOSTICS SYSTEMS,INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 EKF DIAGNOSTICS
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 INSTRUMENTATION LABORATORY
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 NOVA BIOMEDICAL
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PTS DIAGNOSTICS
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 QUIDEL CORPORATION
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 SEKISUI DIAGNOSTICS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SIENCO,INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TRINITY BIOTECH
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 DIFFERENT ASSOCIATIONS FOR DIAGNOSTICS
TABLE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 3 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 4 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 5 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 6 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 21 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 36 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 37 CHINA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 38 CHINA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 39 CHINA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 40 CHINA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 41 CHINA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 42 CHINA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 43 CHINA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 44 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 45 CHINA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 46 CHINA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 47 CHINA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 48 CHINA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 49 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 50 CHINA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 51 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 52 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 53 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 54 JAPAN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 55 JAPAN CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 56 JAPAN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 57 JAPAN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 58 JAPAN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 59 JAPAN HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 60 JAPAN RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 61 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 62 JAPAN HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 JAPAN WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 64 JAPAN VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 65 JAPAN POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 66 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 67 JAPAN POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 68 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 69 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 70 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 71 INDIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 72 INDIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 73 INDIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 74 INDIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 75 INDIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 76 INDIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 77 INDIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 78 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 79 INDIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 INDIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 81 INDIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 82 INDIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 83 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 84 INDIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 85 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 86 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 87 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 88 SOUTH KOREA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 89 SOUTH KOREA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH KOREA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH KOREA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 92 SOUTH KOREA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 93 SOUTH KOREA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH KOREA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 95 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 96 SOUTH KOREA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 SOUTH KOREA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 98 SOUTH KOREA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 99 SOUTH KOREA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 100 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 101 SOUTH KOREA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 102 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 103 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 104 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 105 GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 106 AUSTRALIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 107 AUSTRALIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 108 AUSTRALIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 109 AUSTRALIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 110 AUSTRALIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 111 AUSTRALIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 112 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 113 AUSTRALIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 AUSTRALIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 115 AUSTRALIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 116 AUSTRALIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 117 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 118 AUSTRALIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 119 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 120 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 121 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 122 SINGAPORE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 123 SINGAPORE CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 124 SINGAPORE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 125 SINGAPORE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 126 SINGAPORE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 127 SINGAPORE HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 128 SINGAPORE RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 129 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 130 SINGAPORE HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 SINGAPORE WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 132 SINGAPORE VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 133 SINGAPORE POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 134 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 135 SINGAPORE POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 136 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 137 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 138 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 139 MALAYSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 140 MALAYSIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 141 MALAYSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 142 MALAYSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 143 MALAYSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 144 MALAYSIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 145 MALAYSIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 146 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 147 MALAYSIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 MALAYSIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 149 MALAYSIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 150 MALAYSIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 151 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 152 MALAYSIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 153 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 154 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 155 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 156 THAILAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 157 THAILAND CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 158 THAILAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 159 THAILAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 160 THAILAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 161 THAILAND HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 162 THAILAND RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 163 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 164 THAILAND HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 165 THAILAND WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 166 THAILAND VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 167 THAILAND POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 168 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 169 THAILAND POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 170 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 171 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 172 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 173 INDONESIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 174 INDONESIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 175 INDONESIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 176 INDONESIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 177 INDONESIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 178 INDONESIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 179 INDONESIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 180 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 181 INDONESIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 NDONESIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 183 INDONESIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 184 INDONESIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 185 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 186 INDONESIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 187 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 188 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 189 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 190 PHILIPPINES GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 191 PHILIPPINES CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 192 PHILIPPINES INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 193 PHILIPPINES PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 194 PHILIPPINES CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 195 PHILIPPINES HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 196 PHILIPPINES RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 197 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 198 PHILIPPINES HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 PHILIPPINES WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 200 PHILIPPINES VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 201 PHILIPPINES POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 202 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 203 PHILIPPINES POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 204 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 205 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 206 REST OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CHRONIC DISEASES AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE ASIA-PACIFIC POINT-OF-CARE (POCT) TESTING MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC POINT-OFCARE (POCT) TESTING MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
FIGURE 14 EPIDEMIOLOGY OF CHRONIC CONDITIONS (1990-2015)
FIGURE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019
FIGURE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 20 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 24 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019
FIGURE 28 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019
FIGURE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE (2020-2027)
FIGURE 48 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET: COMPANY SHARE 2019 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
